Evidence map›Paper›PMID 36920967›Full record

ArticlePLoS pathogens2023

Glucosylceramide is essential for Heartland and Dabie bandavirus glycoprotein-induced membrane fusion.

Tian Xia, Xin Wu, Eunjin Hong, Kyle Jung, Chih-Jen Lai, Mi-Jeong Kwak, Hogyu Seo, Stephanie Kim, Zhongyi Jiang, Inho Cha and 1 more

Open access · goldFull text read
In one paragraph

Article in PLoS pathogens, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Tian XiaDepartment of Cancer Biology, Infection Biology Program, and Global Center for Pathogen and Human Health Research, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, United States of America.
Xin WuDepartment of Cancer Biology, Infection Biology Program, and Global Center for Pathogen and Human Health Research, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, United States of America.
Eunjin HongDepartment of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, California, United States of America.
Kyle JungDepartment of Cancer Biology, Infection Biology Program, and Global Center for Pathogen and Human Health Research, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, United States of America.
Chih-Jen LaiDepartment of Cancer Biology, Infection Biology Program, and Global Center for Pathogen and Human Health Research, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, United States of America.
Mi-Jeong KwakDepartment of Cancer Biology, Infection Biology Program, and Global Center for Pathogen and Human Health Research, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, United States of America.
Hogyu SeoDepartment of Cancer Biology, Infection Biology Program, and Global Center for Pathogen and Human Health Research, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, United States of America.
Stephanie KimDepartment of Cancer Biology, Infection Biology Program, and Global Center for Pathogen and Human Health Research, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, United States of America.
Zhongyi JiangDepartment of Cancer Biology, Infection Biology Program, and Global Center for Pathogen and Human Health Research, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, United States of America.
Inho ChaDepartment of Cancer Biology, Infection Biology Program, and Global Center for Pathogen and Human Health Research, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, United States of America.
Jae U JungDepartment of Cancer Biology, Infection Biology Program, and Global Center for Pathogen and Human Health Research, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, United States of America.ORCID 0000-0003-4559-8774
Cleveland Clinic Lerner College of Medicine · USUniversity of Southern California · US

Funding

Molecular Basis of KSHV oncogenesisR35CA200422 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI JUNG, JAE U · 2016 to 2022
$6.1M
KSHV Subunit Vaccine Candidates to Elicit Potent Humoral Immune Reponses against KSHV InfectionR01AI151013 · NIAID · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI OGEMBO, JAVIER GORDON · 2021 to 2025
$4.3M
SFTSV nonstructural protein NSs-mediated immunopathogenesisR01AI140705 · NIAID · UNIVERSITY OF SOUTHERN CALIFORNIA · PI JUNG, JAE U · 2018 to 2022
$4.2M
Genetic evolution, pathogenesis and immune responses in mother to child transmission of ZIKVR01AI140718 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHENG, GENHONG, JUNG, JAE U · 2018 to 2022
$3.8M
Reassortment of Bunyavirus in ticks and animal modelsR01AI171201 · NIAID · CLEVELAND CLINIC LERNER COM-CWRU · PI Jae U Jung · 2022 to 2026
$2.9M
Tickborne SFTS Virus Vaccine DevelopmentR01AI152190 · NIAID · CLEVELAND CLINIC LERNER COM-CWRU · PI JUNG, JAE U · 2020 to 2024
$2.9M
Structural analysis and therapeutic nanobody development of KSHV G-protein coupled receptorR01CA251275 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · PI JUNG, JAE U · 2020 to 2024
$2.5M
KSHVmediated regulation of proline metabolismR01DE028521 · NIDCR · UNIVERSITY OF SOUTHERN CALIFORNIA · PI JUNG, JAE U · 2019 to 2023
$2.4M
Regulation of lymphangiogenesis by KSHV vIRF3R21DE027888 · NIDCR · UNIVERSITY OF SOUTHERN CALIFORNIA · PI JUNG, JAE U · 2018 to 2019
$451k
NCI NIH HHS R01 CA251275NCI NIH HHS R35 CA200422NIAID NIH HHS R01 AI140705NIAID NIH HHS R01 AI140718NIAID NIH HHS R01 AI151013NIAID NIH HHS R01 AI152190NIAID NIH HHS R01 AI171201NIDCR NIH HHS R01 DE028521NIDCR NIH HHS R21 DE027888
6 · The paper itself

Abstract

Due to climate changes, there has been a large expansion of emerging tick-borne zoonotic viruses, including Heartland bandavirus (HRTV) and Dabie bandavirus (DBV). As etiologic agents of hemorrhagic fever with high fatality, HRTV and DBV have been recognized as dangerous viral pathogens that likely cause future wide epidemics. Despite serious health concerns, the mechanisms underlying viral infection are largely unknown. HRTV and DBV Gn and Gc are viral surface glycoproteins required for early entry events during infection. Glycosphingolipids, including galactosylceramide (GalCer), glucosylceramide (GlcCer) and lactosylceramide (LacCer), are a class of membrane lipids that play essential roles in membrane structure and viral lifecycle. Here, our genome-wide CRISPR/Cas9 knockout screen identifies that glycosphingolipid biosynthesis pathway is essential for HRTV and DBV infection. The deficiency of UDP-glucose ceramide glucosyltransferase (UGCG) that produces GlcCer resulted in the loss of infectivity of recombinant viruses pseudotyped with HRTV or DBV Gn/Gc glycoproteins. Conversely, exogenous supplement of GlcCer, but not GalCer or LacCer, recovered viral entry of UGCG-deficient cells in a dose-dependent manner. Biophysical analyses showed that GlcCer targeted the lipid-head-group binding pocket of Gc to form a stable protein-lipid complex, which allowed the insertion of Gc protein into host lysosomal membrane lipid bilayers for viral fusion. Mutagenesis showed that D841 residue at the Gc lipid binding pocket was critical for GlcCer interaction and thereby, viral entry. These findings reveal detailed mechanism of GlcCer glycosphingolipid in HRTV and DBV Gc-mediated membrane fusion and provide a potential therapeutic target for tickborne virus infection.

Indexed as

GlucosylceramidesRNA VirusesAntigens, CDBunyaviridaeGlycoproteinsLactosylceramidesMembrane FusionAntigens, CDCDw17 antigenGlucosylceramidesGlycoproteinsLactosylceramides

Identifiers

PMID36920967
PMCPMC10016662
OpenAlexW4324311412

What OpenQuestion holds

Textfull text, public
LicenceCC BY
reference markers read1
measurements read81
identifiers read11
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.